C5 and COVID-19: A randomised, double-blind, placebo-controlled, multicentre phase 3 trial (PANAMO, NCT04333420) showed that in addition to standard of care (SOC), vilobelimab (formerly IFX-1), a monoclonal antibody which specifically binds complement 5a (C5a), improved survival of invasively mechanically ventilated patients with coronavirus disease 2019 (COVID-19) [1].